NeurologyLive® Friday 5 — September 29, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: IJMSC September/October 2023 Highlights

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

2: Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Five-Year Safety of Ofatumumab in People Living with Relapsing Multiple Sclerosis” presented at AAN 2023. Sponsored By Novartis.

3: NeuroVoices: Craig Blackstone, MD, PhD, FANA, on Helping Path Research Careers for Young Medical Professionals

In this recent Q&A, the chief of the Movement Disorders Division at Mass General Hospital provided context on the goals behind the research careers reimagined course at the recently concluded ANA Annual Meeting.

4: Challenges With Access, Delivery of New ALS Therapeutics: Richard Bedlack, MD, PhD, MS

The director of the Duke ALS Clinic at Duke Health provided perspective on the issues with getting newly approved ALS therapies to patients who need them the most. [WATCH TIME: 4 minutes]

5: The Complex Landscape of NMOSD and MOGAD-Associated Diseases: Erin Longbrake, MD, PhD

The associate professor of neurology at Yale School of Medicine discussed the differentiation of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein -associated disease from multiple sclerosis at IFN 2023. [WATCH TIME: 5 minutes]